MP53-17 CLINICAL VALIDATION OF THE 2005 ISUP GLEASON GRADING SYSTEM IN A COHORT OF INTERMEDIATE AND HIGH RISK MEN UNDERGOING RADICAL PROSTATECTOMY

摘要: In 2005, the International Society of Urological Pathology (ISUP) introduced several modifications to original Gleason system that were intended enhance prognostic power score (GS). The objective this study was clinically validate 2005 ISUP grading for its ability detect metastasis. We queried our institutional RP database men with NCCN localized intermediate high-risk disease undergoing radical prostatectomy (RP) between 1992 and 2010 no additional treatment until time metastatic progression. A case-cohort design utilized. total 333 available samples re-reviewed GS reassigned per system. Cumulative incidence metastasis 0%, 8.4%, 24.5% 44.4% among specimens downgraded, unchanged, had one point increase two increase, respectively. hazard ratio raised in 8 9 compared 7 from 2.77 5.91 3.49 9.31, survival c-index increased 0.70 0.80 when re-graded at 5 years post RP. higher than (0.77 vs 0.64) predicting PCSM 10 regraded improved prediction PCSM. This validates updated using an unambiguous clinical endpoint highlights need reassignment according considering comparisons novel biomarkers clinicopathological variables archival cohorts. PLOS ONE | DOI:10.1371/journal.pone.0146189 January 5, 2016 1 / 13 OPEN ACCESS Citation: Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, et al. (2016) Clinical Validation Grading System a Cohort Intermediate High Risk Men Undergoing Radical Prostatectomy. PLoS 11(1): e0146189. doi:10.1371/journal.pone.0146189 Editor: Xin Gao, Sun Yat-sen University, CHINA Received: October 18, 2015 Accepted: December 14, Published: Copyright: © is open access article distributed under terms Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction any medium, provided author source are credited. Data Availability Statement: All relevant data within paper Supporting Information files. Funding: Kasra Elai Davicione employees GenomeDx Biosciences Inc. remaining authors have conflict interest declare. funder support form salaries [KY ED], but did not role design, collection analysis, decision publish, or preparation manuscript. specific roles these articulated ‘author contributions’ section.